Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022.
| Next-generation cytoDRiVE platform enables precise control of IL12, IL23, IL2, and IFNα in genetically modified T-cells
CAMBRIDGE, Mass., May 17, 2022 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present enhancements to its proprietary cytoDRIVE® technology during a poster presentation at the 25th ASGCT Annual Meeting. The conference is being hosted in Washington, D.C., and virtually, May 16-19, 2022. The data to be presented outline next-generation advancements to Obsidian’s proprietary cytoDRiVE platform technology, which provides a way to precisely control the timing and level of protein function using FDA approved small molecules. Armoring cell therapies with potent cytokines such as IL12 is a promising approach to treating solid tumors, but uncontrolled constitutive expression of these payloads has limited their clinical use due to toxicity. The data to be presented demonstrate that Obsidian’s cytoDRiVE platform enables robust and reversible regulation of multiple cytokines such as IL12, IL23, IL2, and IFNα, potentially enabling their safe use in adoptive cell therapy applications. “These advances in our regulation platform expand the versatility and breadth of potential applications for the cytoDRiVE technology,” commented Jan ter Meulen, M.D., Ph.D., Chief Scientific Officer of Obsidian. “We look forward to continuing to leverage our technology to advance our pipeline of potential therapies designed to expand available treatment options and improve outcomes of patients using enhanced cell therapies, such as engineered tumor infiltrating lymphocytes.” Details of the poster presentation are as follows: Poster Board Number: W-215 Abstract Summary: Cytokines such as IL12 and IFNα have shown great promise in pre-clinical studies when expressed from genetically modified T-cells, however broad use is limited by toxicity from systemic exposure of constitutive expression. If concentration and localization of cytokines and other immunomodulators could be effectively regulated, they would strong candidates for armoring cellular therapies, such as chimeric antigen receptor T cells (CAR-T cells) or tumor infiltrating lymphocytes (TILs). Advancements to the cytoDRiVE platform, based on multimerization of DRDs with homologous or heterologous oligomerization domains to increase their degron effect, enable tight regulation with extremely low cell surface abundance in the absence of drug, and robust induction (10-20 fold) in the presence of drug. Design elements such as membrane-tethering to reduce risk of systemic toxicity and engineering of protease sites for controlled shedding enable fit-for-purpose engineering and potential to regulate multiple cytokines. cytoDRiVE provides full control of the abundance of IL12, IL23, IL2, and IFNα in genetically modified T-cells using a small molecule drug as the on/off switch for precise control of cytokine activity. About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter. Media Contact:
SOURCE Obsidian Therapeutics |
View original content to download multimedia:
